年销超4亿复合磷酸氢钾注射液获批，医药市场持续扩容中！

Core Insights - A new potassium hydrogen phosphate injection (Shanweixi) has been approved for market release by the National Medical Products Administration, entering a growing market with annual sales exceeding 400 million yuan and a year-on-year growth of 27.3% [1][4]. Market Overview - The compound potassium hydrogen phosphate injection is crucial for correcting hypophosphatemia in adults and children, especially when oral supplementation is not feasible, serving as a vital intravenous electrolyte replenishment solution [4]. - The product has been included in the National Medical Insurance Category B for several years, indicating a mature clinical understanding and usage [4]. - Market data from the MoSheng Pharmaceutical Database shows stable growth over the past three years, with sales expected to exceed 400 million yuan in 2024, reflecting a 27.3% increase [4]. Competitive Landscape - Prior to this approval, 24 pharmaceutical companies already held production licenses for this product, with 19 having passed consistency evaluations, indicating a stable competitive landscape [6]. - Despite the existing competition, there remains strong interest, with 15 additional companies currently in the process of applying for generic drug approvals, highlighting ongoing optimism regarding the market value of this product [6][9]. Future Outlook - For new entrants in the pharmaceutical sector, despite facing significant competition, the continuous growth of the market size and clear clinical positioning still provide opportunities for market entry [9]. - As more companies join the market, competition is expected to intensify, which may enhance product accessibility and optimize clinical medication costs [12].